Literature DB >> 28540419

Therapy assessment in prostate cancer using choline and PSMA PET/CT.

Francesco Ceci1, Ken Herrmann2,3, Boris Hadaschik4, Paolo Castellucci5, Stefano Fanti5.   

Abstract

While PET with non-FDG tracers (mainly choline and Ga-PSMA) has commonly been used for restaging in men with biochemically recurrent prostate cancer, as well as for primary staging, it is only recently that a few preliminary studies have addressed the possible use of PET for monitoring the response to systemic therapy of metastatic disease, especially innovative treatments such as abiraterone and enzalutamide. This article aims to evaluate the role of PET imaging with different non-FDG radiotracers for assessment of therapy in advanced prostate cancer patients.

Entities:  

Keywords:  Choline; PSMA; Pet/Ct; Prostate cancer; Therapy assessment; mCRPC

Mesh：

Substances：

Year:  2017        PMID： 28540419     DOI： 10.1007/s00259-017-3723-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


  36 in total

1.  (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.

Authors:  Tiziano Graziani; Francesco Ceci; Paolo Castellucci; Giulia Polverari; Giacomo Maria Lima; Filippo Lodi; Alessio Giuseppe Morganti; Andrea Ardizzoni; Riccardo Schiavina; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-08       Impact factor: 9.236

Review 2.  Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls.

Authors:  Dow-Mu Koh; Matthew Blackledge; Anwar R Padhani; Taro Takahara; Thomas C Kwee; Martin O Leach; David J Collins
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

3.  Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

Authors:  Susan Halabi; Chen-Yen Lin; W Kevin Kelly; Karim S Fizazi; Judd W Moul; Ellen B Kaplan; Michael J Morris; Eric J Small
Journal:  J Clin Oncol       Date:  2014-01-21       Impact factor: 44.544

4.  Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.

Authors:  Tore Bach-Gansmo; Cristina Nanni; Peter T Nieh; Lucia Zanoni; Tronde Velde Bogsrud; Heidi Sletten; Katrine Andersen Korsan; J Kieboom; Funmilayo I Tade; Oluwaseun Odewole; Albert Chau; Penelope Ward; Mark M Goodman; Stefano Fanti; David M Schuster; Frode Willoch
Journal:  J Urol       Date:  2016-10-13       Impact factor: 7.450

5.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

6.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

7.  Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer.

Authors:  Sarah M Schwarzenböck; Matthias Eiber; Günther Kundt; Margitta Retz; Monique Sakretz; Jens Kurth; Uwe Treiber; Roman Nawroth; Ernst J Rummeny; Jürgen E Gschwend; Markus Schwaiger; Mark Thalgott; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-17       Impact factor: 9.236

8.  Tumor clone dynamics in lethal prostate cancer.

Authors:  Suzanne Carreira; Alessandro Romanel; Jane Goodall; Emily Grist; Roberta Ferraldeschi; Susana Miranda; Davide Prandi; David Lorente; Jean-Sebastien Frenel; Carmel Pezaro; Aurelius Omlin; Daniel Nava Rodrigues; Penelope Flohr; Nina Tunariu; Johann S de Bono; Francesca Demichelis; Gerhardt Attard
Journal:  Sci Transl Med       Date:  2014-09-17       Impact factor: 17.956

Review 9.  Imaging metastatic bone disease from carcinoma of the prostate.

Authors:  C Messiou; G Cook; N M deSouza
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

10.  Visceral disease in castration-resistant prostate cancer.

Authors:  C Pezaro; A Omlin; D Lorente; D Nava Rodrigues; R Ferraldeschi; D Bianchini; D Mukherji; R Riisnaes; A Altavilla; M Crespo; N Tunariu; J de Bono; G Attard
Journal:  Eur Urol       Date:  2013-11-22       Impact factor: 20.096
View more
  13 in total

1.  Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment.

Authors:  Larissa Bastos Costa; Marcelo Araujo Queiroz; Felipe de Galiza Barbosa; Rafael Fernandes Nunes; José Flávio Gomes Marin; Carlos Dzik; Carlos Alberto Buchpiguel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-22       Impact factor: 9.236

2.  Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community.

Authors:  Nicolas Aide; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-24       Impact factor: 9.236

3.  The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals.

Authors:  Francesco Ceci; Giulia Polverari; Jeremie Calais; Paolo Castellucci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12       Impact factor: 9.236

Review 4.  Advances in prostate-specific membrane antigen PET of prostate cancer.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  Curr Opin Oncol       Date:  2018-05       Impact factor: 3.645

5.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

6.  Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.

Authors:  Pietro Ghedini; I Bossert; L Zanoni; F Ceci; T Graziani; P Castellucci; V Ambrosini; F Massari; E Nobili; B Melotti; A Musto; S Zoboli; L Antunovic; M Kirienko; A Chiti; C Mosconi; A Ardizzoni; R Golfieri; S Fanti; C Nanni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-30       Impact factor: 9.236

7.  Uptake of Radium-223 Dichloride and Early [18F]NaF PET Response Are Driven by Baseline [18F]NaF Parameters: a Pilot Study in Castration-Resistant Prostate Cancer Patients.

Authors:  Arthur Letellier; Alison C Johnson; Nicolas How Kit; Jean-François Savigny; Alain Batalla; Jean-Jacques Parienti; Nicolas Aide
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

8.  E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.

Authors:  Francesco Ceci; Daniela E Oprea-Lager; Louise Emmett; Judit A Adam; Jamshed Bomanji; Johannes Czernin; Matthias Eiber; Uwe Haberkorn; Michael S Hofman; Thomas A Hope; Rakesh Kumar; Steven P Rowe; Sarah M Schwarzenboeck; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-19       Impact factor: 9.236

9.  Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN7-14 and Antagonist RM26.

Authors:  Siyuan Cheng; Lixin Lang; Zhantong Wang; Orit Jacobson; Bryant Yung; Guizhi Zhu; Dongyu Gu; Ying Ma; Xiaohua Zhu; Gang Niu; Xiaoyuan Chen
Journal:  Bioconjug Chem       Date:  2018-01-09       Impact factor: 4.774

Review 10.  Clinical perspectives of PSMA PET/MRI for prostate cancer.

Authors:  Felipe de Galiza Barbosa; Marcelo Araújo Queiroz; Rafael Fernandes Nunes; José Flávio Gomes Marin; Carlos Alberto Buchpiguel; Giovanni Guido Cerri
Journal:  Clinics (Sao Paulo)       Date:  2018-09-21       Impact factor: 2.365
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.